University of Muenster
Welcome,         Profile    Billing    Logout  
 13 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stelljes, Matthias
IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting
3
210
Europe
MC0518, BAT
medac GmbH
Steroid-refractory Acute Graft-versus-host Disease
08/27
08/30
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/29
NCT03853616 / 2017-002848-32: MB-CART19.1 R/r CD19+ B-cell Malignancies (BCM)

Recruiting
1/2
48
Europe
MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells
Miltenyi Biomedicine GmbH
Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory
12/24
12/24
Wittmann, Maria
NCT05546359 / 2022-002947-23: Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

Recruiting
2/3
410
Europe, Canada, US
Amisulpride Injection, Barhemsys, Dexamethasone, Decadron
Acacia Pharma Ltd, Amicus CD LLC, Premier Research Group plc
Nausea and Vomiting, Postoperative
06/25
12/25
MODIFYCSX, NCT06279793: Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients

Recruiting
2
120
Europe
Long-chain n-3 fatty acids, Omegaven®, Intravenous 0.9% Sodium Chloride, Saline Infusion
GCP-Service International West GmbH, University Hospital, Bonn, University Hospital Muenster, University Hospital Goettingen, University Hospital Schleswig-Holstein, Charite University, Berlin, Germany, Wuerzburg University Hospital
Cardiac Surgery, High Risk Patients, Intensive Care Unit, Cardiopulmonary Bypass, Valve Surgeries
12/24
12/25
Lenz, Georg
COPA-R-CHOP, NCT04263584: Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL

Active, not recruiting
2
62
Europe
Copanlisib, R-CHOP Chemotherapy
University Hospital Muenster, Bayer
Diffuse Large B Cell Lymphoma
04/25
04/25
Bögemann, Martin
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Recruiting
3
430
Europe
Concomitant coaching
AIO-Studien-gGmbH, Pfizer, Crolll Gmbh
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
01/24
07/24
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

Recruiting
3
250
Europe
Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel
Jena University Hospital, Bayer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
07/25
01/27
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Recruiting
3
300
Europe
Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT
UNICANCER, Bayer
Prostate Cancer Metastatic
03/28
09/37
ADAM, NCT04295447 / 2018-004329-10: Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Active, not recruiting
2
190
Europe
Standard of care, Apalutamide 60Mg Tab
Universität Münster, Janssen Pharmaceutica N.V., Belgium
Prostatic Neoplasms
11/28
11/28

Download Options